MedPage Today on MSN

Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke

N EW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse ...
Toronto Life on MSN

The Influentials 2025

In a world first, Lipsman and his team in Sunnybrook’s Hurvitz Brain Sciences Program non-invasively breached the blood-brain ...